ADIL (Adial) Earnings growth in current year

Official company branding of adialpharma.com (ADIL)

Adial Pharmaceuticals (ADIL) is facing a liquidity shortage due to costly trials in the absence of sales. The annual earnings per share growth trajectory reflects the impact of market expectations, where the 78.50 level serves as the current value. Adial Pharmaceuticals is developing the AD04 molecule through partnerships and M&A, implementing genetically targeted alcoholism therapy to improve patient treatment precision.

ADIL - Adial Pharmaceuticals Earnings growth in current year over the range 07/04/2022 - 10/29/2026

Analytical breakdowns and data insights for company Adial Pharmaceuticals Inc. (ADIL)

- price and consensus price forecast:
Stock Quotes Adial Pharmaceuticals Inc.|ADIL - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Adial Pharmaceuticals|ADIL - Enterprise Value
- book capitalization data:
Equity per Share Adial Pharmaceuticals|ADIL - Book Capitalization|Market Capitalization to Book Value adialpharma.com|ADIL - Company Total Assets
- debt burden and liquidity indicators:
Total Debt to Capital Adial Pharmaceuticals|ADIL - Long-Term Debt to Equity|Short-Term Debt to Equity Adial Pharmaceuticals|ADIL - Company Total Debt|Debt to Net Assets Ratio Adial Pharmaceuticals, Inc.|ADIL - Company Long-Term Debt|Current Liabilities Adial Pharmaceuticals|Intermediate Coverage Ratio adialpharma.com
- earnings and market ratios statistics:
ADIL - Net Profit|Projected Future Earnings Adial Pharmaceuticals|ADIL - Price to Earnings Ratio|Future Price to Earnings Multiple Adial|ADIL - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Adial Pharmaceuticals|ADIL - Operating profit EBITDA|Net earnings per share (EPS TTM) Adial Pharmaceuticals|ADIL - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months adialpharma.com|ADIL - Earnings growth in current year|Expected net earnings per share growth next year Adial Pharmaceuticals
- sales volume and revenue information:
ADIL - Company Sales|Projected Sales Volume Adial Pharmaceuticals|ADIL - Market Cap to Revenue|Price to Expected Revenue Ratio Adial Pharmaceuticals
Summary company analysis:adialpharma.com (ADIL)
Manufactured product of Adial Pharmaceuticals, Inc.

The assessment of the business's credit and operational quality is based on the company's ability to generate net income per share. This indicator measures the annual change in EPS, where revenue growth offsets the impact of debt load and liquidity risks. For Adial Pharmaceuticals (ADIL), the costs of ESG transformation in packaging and logistics directly influence the annual percentage dynamics of earnings per share.

Main competitors

Net earnings per share growth this year Indivior Group|COLL (collegiumpharma.com) - Earnings growth in current year|Net earnings per share growth this year thecronosgroup.com (CRON)|Earnings per share growth in current year Tweed (CGC)|Expected net earnings per share growth this year High Tide|Earnings per share growth in current year Aurora Cannabis Inc. ACB|Earnings per share increase in current year ACHV|Skye Bioscience Inc. - Earnings growth in current year|ANEB: Earnings per share growth in current year|Canndoc (INCR) - Earnings per share growth in current year|NTRB - Expected net earnings per share growth this year|Net earnings per share growth this year NSRX|Earnings growth in current year igcinc.us|Earnings growth in current year MIRA|floragrowth.ca (FLGC) - Net earnings per share change in current year|Earnings growth in current year IMCC (IM Cannabis Corp)|Artelo - Earnings per share growth in current year|ensysce.com - Earnings growth in current year|TTNP - Earnings growth in current year|GNLN (Greenlane Holdings) - Net earnings per share growth this year|Net earnings per share growth this year InMed Pharmaceuticals|Earnings per share growth in current year Akanda Corporation|Earnings per share growth rate in current year Enveric Biosciences Inc ENVB|Earnings per share growth in current year Bright Green Corp (BGXX)|Expected net earnings per share growth this year Hempacco